VCM
AXSM icon

Voleon Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Voleon Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.7M Sell
84,433
-63,434
-43% -$13.8M 0.38% 58
2026
Q1 		$25M Buy
147,867
+37,688
+34% +$6.51M 0.54% 32
2025
Q4 		$20.1M Buy
110,179
+93,445
+558% +$13M 0.43% 41
2025
Q3 		$2.03M Buy
+16,734
New +$1.88M 0.05% 308

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Voleon Capital Management's AXSM Position: Q2 2026 in Review

Voleon Capital Management reduced its Axsome Therapeutics (AXSM) stake by 43% in Q2 2026, selling an estimated $13.8M and leaving 84,433 shares worth $20.7M. The position accounts for 0.38% of the portfolio, ranked #58.

Voleon Capital Management first reported a position in AXSM in Q3 2025 and has held it in 4 quarters since. The position peaked at $25M in Q1 2026. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Voleon Capital Management held 84,433 shares of Axsome Therapeutics worth $20.7M as of Q2 2026.
  • Voleon Capital Management sold 63,434 Axsome Therapeutics shares in Q2 2026, an estimated $13.8M.
  • Axsome Therapeutics made up 0.38% of Voleon Capital Management's portfolio in Q2 2026, its #58 holding.
  • Voleon Capital Management first reported a position in Axsome Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Voleon Capital Management's Axsome Therapeutics position peaked at $25M in Q1 2026.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Voleon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.